Helsinki, Finland, Oct 26, 2012 – HVR Cardio International Ltd Oy today announced that the investigators at Helsinki University Hospital have successfully completed the recruitment of patients for the first phase of the clinical study evaluating the safety and performance of the HVR Cardio Helix Ring in adults undergoing mitral valve repair surgery. The preliminary results after a total of 36 patient months in the clinical study show consistent and sustained hemodynamic valve performance and support the unique advantages of the helix ring technology. All the safety and performance study objectives have so far been achieved.
The second phase of the clinical study is planned to commence as a multi-center study in several European countries in Q1 2013.
The HVR Cardio Helix Ring leverages the company’s proprietary helix-technology platform featuring a safe and elegant mitral valve repair and replacement technique. HVR Cardio’s helix based products may benefit patients by enabling small-incision surgical approaches and reduced operative times, leading to potentially reduced morbidity and faster recovery also for patients undergoing complex cardiac procedures. The HVR Cardio helix-technology provides also interesting and promising opportunities for catheter-based mitral valve interventions.
About HVR Cardio International Ltd Oy
HVR Cardio International Ltd Oy is a clinical-stage medical technology company developing innovative products for mitral valve repair and replacement based on the company’s proprietary helix technology. The company, based in Helsinki, Finland, was established 2002 and is backed by leading Nordic venture capital funds.
Additional company information can be found at www.HVR Cardio.com.
Olli Keränen, CEO +358 50 3567090